MME and heart failure: With the publication of paradigm-HF trial (prospective comparison of ARNI with ACEI to determine impact on global mortality in heart failure) in 2014 [1] angiotensin receptor blocker–neprilysin inhibitors (ARNI) became a new promising class of drugs for the treatment of patients with heart failure with reduced ejection fraction (HFrEF).